ENTITY – Page 5

Data Lakes & FAIR Principles: Making Scientific Data Accessible and Actionable

1 week ago talkbio0Tagged accessible, Data Lakes, Data Management, Fair Language Proficiency, Findable, Interoperable, Principles, research, Scientific Data

Data Lakes; FAIR Principles; Scientific Data; Findable; Accessible; Interoperable; Reusable; Research Data Management

Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times

1 week ago talkbio0Tagged adaptation, Apis (invertebrate), Clinical Trials, drug price, Generalized, Investments, manufacturing uncertainty, Market, Pharma, Policy, regulatory environment, Reinvention, resilience, strategic reserves, supply chain

pharma; resilience; reinvention; supply chain; manufacturing uncertainty; regulatory environment; global market adaptation; funding; investment; clinical trials; drug pricing policy; APIs; strategic reserves

UK Drugmakers and Government at Impasse Over New Medicine Rebate Scheme

1 week ago talkbio0Tagged Drug Industry, drugmakers, Government, Health Services, National, Mediation, rates, statutory scheme, UK, valproic acid glucuronide

UK; drugmakers; medicine rebate; government negotiations; VPAG; statutory scheme; pharmaceutical industry; National Health Service; rebate rates

Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted

1 week ago talkbio0Tagged 15%, brand-name drugs, EU, Evaluation, Generic Drugs, Sectioning technique, tariff, tariff exemption, TNFRSF19 gene, transatlantic trade, Trump administration

15% tariff; pharmaceuticals; EU; Trump administration; generic drugs; trade deal; tariff exemption; brand-name drugs; transatlantic trade; Section 232 investigation

AbbVie’s Rinvoq Achieves Second Phase 3 Win in Alopecia Areata Trials

2 weeks ago talkbio0Tagged AbbVie, Alopecia, Eyebrow structure, Eyelash, hair regrowth, Rinvoq, safety profile, Salts, Score, upadacitinib

AbbVie; Rinvoq; upadacitinib; alopecia areata; Phase 3 clinical trial; hair regrowth; SALT score; eyebrows; eyelashes; safety profile

Gilead’s Kite to Acquire Interius for $350M, Advancing In Vivo CAR-T Therapy

2 weeks ago talkbio0Tagged Acquisition, CAR-T, CAR-T therapy, Cell Therapy, Gilead, in vivo, Interius BioTherapeutics, Kite, device (physical object), Tecartus, Yescarta

Gilead; Kite; Interius BioTherapeutics; CAR-T therapy; in vivo CAR-T; acquisition; off-the-shelf cell therapy; $350 million; biotech; Yescarta; Tecartus; cell therapy platform